Argenx Se (ARGX) Stock Forecast & Price Target

Compare

589 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARGX Analyst Ratings

Strong Buy

19 Buy

1 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Argenx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARGX Stock 12 Month Forecast

Average Price Target

$752.26

▲(29.57%Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Argenx Se in the last 3 months. The average price target is $752.26 with a high forecast of $1,065.00 and a low forecast of $620.00. The average price target represents a 29.57% change from the last price of $580.59.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"370":"$370","544":"$544","718":"$718","892":"$892","1066":"$1,066"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1065,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.06K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":752.26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$752.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":620,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$620.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[370,544,718,892,1066],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,584.6,621.5538461538462,658.5076923076923,695.4615384615385,732.4153846153846,769.3692307692307,806.323076923077,843.2769230769231,880.2307692307693,917.1846153846154,954.1384615384616,991.0923076923077,1028.0461538461539,{"y":1065,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,584.6,597.496923076923,610.3938461538462,623.2907692307692,636.1876923076924,649.0846153846154,661.9815384615384,674.8784615384616,687.7753846153846,700.6723076923076,713.5692307692308,726.4661538461538,739.363076923077,{"y":752.26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,584.6,587.323076923077,590.0461538461539,592.7692307692308,595.4923076923077,598.2153846153847,600.9384615384615,603.6615384615385,606.3846153846154,609.1076923076923,611.8307692307692,614.5538461538462,617.2769230769231,{"y":620,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":371.02,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":434.22,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 69,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":516.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":517.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":547.28,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":595.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":617.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":615,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":655.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":624.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":567.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":639.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":584.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,065

Average Price Target$752.26

Lowest Price Target$620.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$639

Buy

10.06%

Upside

Upgraded

06/06/25

Argenx Se's strong financial performance and positive earnings call are the most significant contributors to its overall score. However, technical indicators and valuation suggest caution, as the stock is trading below its long-term moving averages and appears overvalued compared to the market.

David NierengartenWedbush

Wedbush

$715

Buy

23.15%

Upside

Reiterated

06/02/25

Argenx selloff misses growth potential for PFS format, says WedbushArgenx selloff misses growth potential for PFS format, says Wedbush

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/29/25

Argenx's Promising ALKIVIA Study Results Justify Buy Rating

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/22/25

TD Cowen Remains a Buy on Argenx Se (ARGX)

Samantha SemenkowCiti

Citi

$803

Buy

38.31%

Upside

Reiterated

05/21/25

Argenx Se: Strong Growth Prospects and Attractive Buying Opportunity Amid Vyvgart Expansion and Upcoming Catalysts

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$720

Buy

24.01%

Upside

Reiterated

05/15/25

H.C. Wainwright Reaffirms Their Buy Rating on Argenx Se (ARGX)

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$780

Buy

34.35%

Upside

Reiterated

05/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vor Biopharma (NASDAQ: VOR), Clearside Biomedical (NASDAQ: CLSD) and Argenx Se (NASDAQ: ARGX)

Tazeen AhmadBank of America Securities

Bank of America Securities

$804

Buy

38.48%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT), Apellis Pharmaceuticals (NASDAQ: APLS) and Argenx Se (NASDAQ: ARGX)

Jason ButlerCitizens JMP

Citizens JMP

$701→$699

Buy

20.39%

Upside

Reiterated

05/14/25

Argenx price target lowered to $699 from $701 at Citizens JMPArgenx price target lowered to $699 from $701 at Citizens JMP

Joel BeattyRobert W. Baird

Robert W. Baird

$680

Buy

17.12%

Upside

Upgraded

05/13/25

Argenx Se: Buy Rating Affirmed Amid Pricing Strategy Confidence and Promising Growth Prospects

Thomas SmithLeerink Partners

Leerink Partners

$750

Buy

29.18%

Upside

Reiterated

05/09/25

Leerink Partners on argenx SE (ARGX): Share Pullback Creates Buying OpptyLeerink Partners analyst Thomas J. Smith reiterated an Outperform rating and $750.00 price target on argenx SE (NASDAQ: ARGX)

Joon LeeTruist Financial

Truist Financial

$700

Buy

20.57%

Upside

Reiterated

05/09/25

Argenx Se (ARGX) Gets a Buy from Truist Financial

Yatin SunejaGuggenheim

Guggenheim

$1,100→$1,065

Buy

83.43%

Upside

Reiterated

05/09/25

Argenx price target lowered to $1,065 from $1,100 at GuggenheimArgenx price target lowered to $1,065 from $1,100 at Guggenheim

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$713→$750

Buy

29.18%

Upside

Reiterated

05/09/25

Evercore ISI Remains a Buy on Argenx Se (ARGX)

James GordonJ.P. Morgan

J.P. Morgan

$805→$775

Buy

33.48%

Upside

Reiterated

05/09/25

argenx SE (ARGX) PT Lowered to $775 at JPMorganJPMorgan analyst James Gordon lowered the price target on argenx SE (NASDAQ: ARGX) to $775.00 (from $805.00) while maintaining a Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$639

Buy

10.06%

Upside

Upgraded

06/06/25

David NierengartenWedbush

Wedbush

$715

Buy

23.15%

Upside

Reiterated

06/02/25

Argenx selloff misses growth potential for PFS format, says WedbushArgenx selloff misses growth potential for PFS format, says Wedbush

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/29/25

Argenx's Promising ALKIVIA Study Results Justify Buy Rating

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/22/25

TD Cowen Remains a Buy on Argenx Se (ARGX)

Samantha SemenkowCiti

Citi

$803

Buy

38.31%

Upside

Reiterated

05/21/25

Argenx Se: Strong Growth Prospects and Attractive Buying Opportunity Amid Vyvgart Expansion and Upcoming Catalysts

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$720

Buy

24.01%

Upside

Reiterated

05/15/25

H.C. Wainwright Reaffirms Their Buy Rating on Argenx Se (ARGX)

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$780

Buy

34.35%

Upside

Reiterated

05/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vor Biopharma (NASDAQ: VOR), Clearside Biomedical (NASDAQ: CLSD) and Argenx Se (NASDAQ: ARGX)

Tazeen AhmadBank of America Securities

Bank of America Securities

$804

Buy

38.48%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT), Apellis Pharmaceuticals (NASDAQ: APLS) and Argenx Se (NASDAQ: ARGX)

Jason ButlerCitizens JMP

Citizens JMP

$701→$699

Buy

20.39%

Upside

Reiterated

05/14/25

Argenx price target lowered to $699 from $701 at Citizens JMPArgenx price target lowered to $699 from $701 at Citizens JMP

Joel BeattyRobert W. Baird

Robert W. Baird

$680

Buy

17.12%

Upside

Upgraded

05/13/25

Argenx Se: Buy Rating Affirmed Amid Pricing Strategy Confidence and Promising Growth Prospects

Thomas SmithLeerink Partners

Leerink Partners

$750

Buy

29.18%

Upside

Reiterated

05/09/25

Leerink Partners on argenx SE (ARGX): Share Pullback Creates Buying OpptyLeerink Partners analyst Thomas J. Smith reiterated an Outperform rating and $750.00 price target on argenx SE (NASDAQ: ARGX)

Joon LeeTruist Financial

Truist Financial

$700

Buy

20.57%

Upside

Reiterated

05/09/25

Argenx Se (ARGX) Gets a Buy from Truist Financial

Yatin SunejaGuggenheim

Guggenheim

$1,100→$1,065

Buy

83.43%

Upside

Reiterated

05/09/25

Argenx price target lowered to $1,065 from $1,100 at GuggenheimArgenx price target lowered to $1,065 from $1,100 at Guggenheim

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$713→$750

Buy

29.18%

Upside

Reiterated

05/09/25

Evercore ISI Remains a Buy on Argenx Se (ARGX)

James GordonJ.P. Morgan

J.P. Morgan

$805→$775

Buy

33.48%

Upside

Reiterated

05/09/25

argenx SE (ARGX) PT Lowered to $775 at JPMorganJPMorgan analyst James Gordon lowered the price target on argenx SE (NASDAQ: ARGX) to $775.00 (from $805.00) while maintaining a Overweight rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Argenx Se

1 Month

xxx

Success Rate

13/18 ratings generated profit

Average Return

+6.91%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +6.91% per trade.

3 Months

xxx

Success Rate

12/18 ratings generated profit

Average Return

+9.05%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +9.05% per trade.

1 Year

Joel BeattyRobert W. Baird

Success Rate

18/20 ratings generated profit

Average Return

+25.74%

upgraded a buy rating 25 days ago

Copying Joel Beatty's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +25.74% per trade.

2 Years

xxx

Success Rate

20/20 ratings generated profit

Average Return

+33.93%

upgraded a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARGX Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARGX has received 39 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ARGX average Analyst price target in the past 3 months is 752.26.

Each month's total comprises the sum of three months' worth of ratings.

ARGX Financial Forecast

ARGX Earnings Forecast

Next quarter’s earnings estimate for ARGX is $2.99 with a range of $2.09 to $4.19. The previous quarter’s EPS was $2.58. ARGX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ARGX has Outperformed its overall industry.

ARGX Sales Forecast

Next quarter’s sales forecast for ARGX is $868.61M with a range of $752.00M to $935.80M. The previous quarter’s sales results were $790.05M. ARGX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ARGX has Outperformed its overall industry.

ARGX Stock Forecast FAQ

What is ARGX’s average 12-month price target, according to analysts?

Based on analyst ratings, Argenx Se’s 12-month average price target is 752.26.

What is ARGX’s upside potential, based on the analysts’ average price target?

Argenx Se has 29.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARGX a Buy, Sell or Hold?

Argenx Se has a consensus rating of Strong Buy which is based on 19 buy ratings, 1 hold ratings and 0 sell ratings.

What is Argenx Se’s price target?

The average price target for Argenx Se is 752.26. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,065.00 ,the lowest forecast is $620.00. The average price target represents 29.57% Increase from the current price of $580.59.

What do analysts say about Argenx Se?

Argenx Se’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of ARGX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Argenx Se (ARGX) Stock Forecast & Price Target

ARGX Analyst Ratings

ARGX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Argenx Se

ARGX Analyst Recommendation Trends

ARGX Financial Forecast

ARGX Earnings Forecast

ARGX Sales Forecast

ARGX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts